Being diagnosed with cancer that has spread within the abdominal cavity can be overwhelming for patients and their families. Along with understanding the diagnosis, patients often have questions about available treatments, recovery, and the possibility of returning to their normal routine. One treatment that may be considered for selected cases is HIPEC surgery.
HIPEC stands for Hyperthermic Intraperitoneal Chemotherapy. It combines surgery to remove visible cancer deposits with heated chemotherapy delivered directly into the abdominal cavity. Patients searching for HIPEC surgery in Karol Bagh can benefit from understanding how this specialised procedure works and why an individual assessment is essential before deciding on treatment.
HIPEC is generally performed as part of a two-stage treatment approach. First, the surgeon attempts to remove visible cancer deposits from the abdominal cavity. This procedure is called cytoreductive surgery. Once the visible disease has been removed as completely as possible, heated chemotherapy is circulated within the abdominal cavity for a specified period.
The chemotherapy solution is usually maintained at a controlled temperature, commonly around 41–43°C, depending on the treatment protocol. Heating may improve the effectiveness of certain chemotherapy medicines against cancer cells remaining in the abdominal cavity.
Because the medication is delivered directly into the affected area, HIPEC differs from conventional intravenous chemotherapy. However, it is a major procedure and is not suitable for every patient with abdominal cancer.
HIPEC may be considered for selected patients with cancers involving the peritoneum, the lining of the abdominal cavity. Depending on the cancer type, disease extent, and clinical circumstances, these may include:
Ovarian cancer that has spread within the abdominal cavity.
Primary peritoneal cancer.
Appendiceal cancers, including certain mucinous tumours.
Selected colorectal cancers with peritoneal metastases.
Some other abdominal cancers in carefully selected cases.
The suitability of HIPEC varies considerably between cancer types. It is not a universal treatment for advanced cancer, and its potential benefits must be weighed against its risks.
Eligibility depends on several factors, including the type of cancer, the extent and distribution of disease, previous treatments, general fitness, and whether the surgeon believes the visible cancer can be removed adequately.
Before recommending treatment, the medical team may review imaging studies, biopsy findings, blood tests, previous chemotherapy records, and overall health. Some patients may need additional investigations or treatment before surgery.
A consultation with a surgical oncologist experienced in cytoreductive surgery and HIPEC can help patients understand their options, likely outcomes, and alternative treatments.
Recovery after HIPEC surgery can take several weeks and sometimes longer, depending on the extent of surgery and the patient's overall condition. Hospitalisation may be required for monitoring, pain management, nutritional support, and observation of bowel function.
Temporary fatigue, reduced appetite, and changes in digestion may occur during recovery. Some patients may also experience complications, such as infections, bleeding, blood clots, or problems involving the bowel or other abdominal organs. The treating team will explain the risks relevant to the individual case.
Following discharge, patients may need regular appointments, dietary guidance, gradual physical activity, and further cancer treatment when indicated.
When exploring HIPEC surgery in Karol Bagh, patients should look for a qualified surgical oncology team with experience in complex abdominal cancer procedures. It is worth asking about the surgeon's experience, the hospital's intensive care and emergency support, expected recovery time, treatment alternatives, and the overall care plan.
Patients should also discuss the financial aspects of treatment, including hospitalisation, investigations, medicines, and follow-up care, before making a decision.
No. It is appropriate only for selected cancers and patients. Eligibility depends on the diagnosis, disease spread, overall health, and the feasibility of removing visible cancer deposits.
Recovery varies according to the complexity of surgery and individual health. Hospitalisation may last several days or longer, while regaining strength can take weeks or months.
No. Although it may improve outcomes for selected patients, it cannot guarantee a cure. The expected benefit depends on the cancer type, disease extent, and other clinical factors.
